

SUPPLEMENTAL MATERIAL

Supplemental Table I. Demographic and clinical characteristics of POINT participants who provided DNA for this substudy versus those who did not, stratified by treatment group.

Characteristic	Provided DNA			No DNA		
	Aspirin n=475	Clopidogrel- Aspirin n=475	Total n=932	Aspirin n=1974	Clopidogrel- Aspirin n=1975	Total n=3949
Age in years, median (IQR)	63 (54-73)	63 (53-72)	63 (53.5-72)	65 (56-74)	65 (56-75)	65 (56-75)
Hours from symptom onset to randomization, median (IQR)	7 (5-10)	7 (5-10)	7 (5-10)	7 (5-10)	7 (5-10)	7 (5-10)
Male, No (%)	271 (57.1)	259 (56.7)	530 (56.9)	1080 (54.7)	1076 (54.5)	2156 (54.6)
White race	337 (70.9)	323 (70.7)	660 (70.8)	1444 (73.2)	1451 (73.5)	2895 (73.3)
Black/AA	110 (23.2)	106 (23.2)	216 (23.2)	383 (19.4)	367 (18.6)	750 (19.0)
Other	28 (5.9)	28 (6.1)	56 (6.0)	147 (7.4)	157 (7.9)	304 (7.7)
Medical history						
Heart disease	40 (8.4%)	46 (10.1%)	86 (9.3%)	200 (10.2%)	211 (10.7%)	411 (10.4%)
Congestive heart failure	7 (1.5%)	14 (3.1%)	21 (2.3%)	55 (2.8%)	50 (2.5%)	105 (2.7%)
Atrial fibrillation	3 (0.6%)	4 (0.9%)	7 (0.8%)	15 (0.8%)	27 (1.4%)	42 (1.1%)
Valvular heart disease	7 (1.5%)	6 (1.3%)	13 (1.4%)	27 (1.4%)	43 (2.2%)	70 (1.8%)
Hypertension	325 (68.7%)	321 (70.2%)	646 (69.5%)	1355 (69.0%)	1372 (69.8%)	2727 (69.4%)
Diabetes mellitus	132 (27.8%)	113 (24.9%)	245 (26.4%)	530 (26.9%)	565 (28.7%)	1095 (27.8%)
Current or prior smoker	214 (45.1%)	220 (48.1%)	434 (46.6%)	951 (48.2%)	951 (48.2%)	1902 (48.2%)
Index event						
TIA	200 (42.1%)	202 (44.2%)	402 (43.1%)	852 (43.2%)	854 (43.2%)	1706 (43.2%)
Minor stroke	275 (57.9%)	255 (55.8%)	530 (56.9%)	1122 (56.8%)	1121 (56.8%)	2243 (56.8%)
Prior medication use						
Aspirin	281 (59.2%)	268 (58.6%)	549 (58.9%)	1116 (56.5%)	1149 (58.2%)	2265 (57.4%)
Clopidogrel	10 (2.1%)	7 (1.5%)	17 (1.8%)	32 (1.6%)	41 (2.1%)	73 (1.8%)
Antihypertensives	171 (53.3%)	161 (52.6%)	332 (53.0%)	528 (51.5%)	541 (53.0%)	1069 (52.2%)
Statins	189 (39.9%)	176 (38.5%)	365 (39.2%)	743 (37.6%)	782 (39.6%)	1525 (38.6%)
Other lipid lowering treatment	18 (3.8%)	12 (2.6%)	30 (3.2%)	112 (5.7%)	97 (4.9%)	209 (5.3%)